drugset / Trial / NCT06665256
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
RandomizedParallel-groupOpen-labelTreatment
Summary
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM)
Timeline
- Start
- 2024-12-17
- Primary completion
- 2029-03-09
- Completion
- 2032-11-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rapcabtagene autoleucel | Cell therapy | — | Other |